Myocardial Infarction News and Research

RSS

Scripps researcher receives U-M's Eric J. Topol Professorship in Cardiovascular Medicine

The University of Michigan Medical School today announced the establishment of the Eric J. Topol Professorship in Cardiovascular Medicine. A world-renowned cardiologist, Dr. Topol is currently chief academic officer at Scripps Health and a senior cardiologist practitioner at Scripps Clinic.

27 Oct 2011

DFG announces establishment of twelve research units

The Deutsche Forschungsgemeinschaft has established nine new Research Units and three Clinical Research Units. The decision was made by the Joint Committee of Germany's central research funding organisation at its October meeting in Bonn.

22 Oct 2011

CJC publishes paper on the timing of coronary stenting

The Canadian Journal of Cardiology has published a paper on the timing of coronary stenting, a thought-provoking paper that challenges one of the dogmas of acute heart attack management today.

20 Oct 2011

Cord blood stem cells can repair cardiac muscle after heart attack

At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient's own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart attack.

14 Oct 2011

ESC to deliver educational programme on cardiovascular disease in Beijing

At over 40%, the mortality rate due to cardiovascular disease (CVD) in China is amongst the highest in the world- and has been rightly described as an epidemic. Its population faces a catalogue of CVD risk factor statistics that expose high levels of obesity, diabetes, cholesterol and blood pressure, and a smoking habit within males that is proving stubborn to address.

13 Oct 2011

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.

4 Oct 2011

VDC and P.A.D. Coalition present annual research awards at VDF's eighth annual meeting

The Venous Disease Coalition (VDC) and Peripheral Arterial Disease Coalition presented their annual research awards at the Vascular Disease Foundation's eighth annual meeting in Washington.

30 Sep 2011

Genetic variant may increase severity of coronary artery disease in patients with diabetes

Researchers at Washington University School of Medicine in St. Louis have identified the first genetic variant associated with severity of coronary artery disease in patients with type 2 diabetes.

29 Sep 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Traffic fumes can raise risk for heart attack for at least six hours: Study

According to British researchers breathing in heavy traffic fumes can trigger a heart attack. Heart attack risk is raised for about six hours post-exposure and goes down again after that, researchers found. They say in the British Medical Journal that pollution probably hastens rather than directly cause attacks. But repeated exposure is still bad for health, they say, substantially shortening life expectancy, and so the advice to people remains the same - avoid as far as is possible.

22 Sep 2011

Scientists discover 10 types of unique proteins in patients with stroke or heart attack

A simple blood test is all it could take to tell if you are going to have a heart attack or stroke. A team of international scientists have discovered more than 10 types of unique proteins which are commonly present in the blood of a person who recently suffered a stroke or heart attack.

22 Sep 2011

Enrollment complete in STENTYS Self-Apposing Stent clinical study for treatment of AMI

STENTYS S.A., a medical technology company that is commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the 500-patient target of the international APPOSITION III study for its Self-Apposing Stent.

21 Sep 2011

U-M Professor to review data from three prominent studies on heart failure

Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes and types of heart failure vary greatly, and treatment must be tailored to each patient. In some cases, doctors will prescribe a class of diuretic drugs called aldosterone antagonists.

20 Sep 2011

FDA approves Amphastar's ANDA for Enoxaparin Sodium Injection

Watson Pharmaceuticals, Inc. today announced that Amphastar Pharmaceuticals, Inc., has received U.S. Food and Drug Administration approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 100mg/mL and 150mg/mL strengths.

20 Sep 2011

Enrollment commences in MINI-AMI study of Impella in STEMI patients

Abiomed, Inc., a leading provider of breakthrough heart support technologies, today announced the first patient enrolled in MINI-AMI, an FDA prospective, randomized, controlled multi-center study to assess the role of 24-hours of direct unloading of the left ventricle with Impella 2.5 support to reduce infarct size in patients with ST-elevation myocardial infarction (STEMI) without cardiogenic shock.

19 Sep 2011

Combination of prasugrel plus ASA can treat acute coronary syndrome

In order to better prevent blood clots, the drugs clopidogrel or prasugrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid.

16 Sep 2011

TCT to showcase major scientific research breakthroughs in cardiovascular medicine

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world's leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

16 Sep 2011

CRF announces late breaking trials & first report investigations to be presented at TCT 2011

The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2011 scientific symposium. Presented in partnership with the American College of Cardiology (ACC), TCT 2011 is the world’s leading educational meeting specializing in interventional cardiovascular medicine and will take place November 7-11, 2011 in San Francisco.

15 Sep 2011

Researchers demonstrate connection between circadian rhythm, platelet function and cardiovascular risk

Researchers at Brigham and Women's Hospital (BWH) have demonstrated that the circadian system, the body's internal clock, regulates human platelet function and causes a peak in platelet activation corresponding to the known morning peak in adverse cardiovascular events. These findings are published in PLoS ONE on September 8, 2011.

9 Sep 2011

Mesoblast receives EMA clearance to initiate Revascor Phase 2 trial for heart attacks

Global regenerative medicine company, Mesoblast Limited, today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack.

5 Sep 2011